About Cerulean Pharma
Cerulean Pharma is a company based in Cambridge (United States) founded in 2006 was acquired by Daré Bioscience in March 2017. Cerulean Pharma has raised $88.7 million across 11 funding rounds from investors including ARE, Bessemer Venture Partners and Daré Bioscience. The company has 20 employees. Cerulean Pharma offers products and services including Prescription Medications, Over-the-Counter Drugs, and Generic Drugs. Cerulean Pharma operates in a competitive market with competitors including Jazz Pharmaceuticals, Moderna, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Cambridge, United States
- Employees 20
- Stage Public
- SectorsTechnologyHealthcare
- Website ceruleanrx.com
- Social LinkedIn
- Acquired by Daré Bioscience (Mar 2017)
- Legal Name Cerulean Pharma Inc.
- Total Equity Funding$88.7M (USD)
in 11 rounds
- InvestorsARE
& 7 more
- Employee Count20
- Acquired byDaré Bioscience
(Mar 2017)
Products & Services of Cerulean Pharma
Cerulean Pharma offers a comprehensive portfolio of products and services, including Prescription Medications, Over-the-Counter Drugs, and Generic Drugs.
Platform for ordering and delivering regulated prescription drugs securely.
Sale of non-prescription items like vitamins and analgesics for daily use.
Lower-cost alternatives to brand drugs for various health conditions.
Funding Insights of Cerulean Pharma
Cerulean Pharma has successfully raised a total of $88.7M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $88.7M
- Total Rounds 11
- First Round $12.1M
(Mar 2007)
- Investors Count 7
Latest 10 of 11 funding rounds of Cerulean Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2016 | – | Post-IPO | – | – | – |
| Apr 2015 | $35M | Post-IPO | – | – | – |
| Jan 2015 | $26M | Debt – Venture | – | – | |
| Nov 2012 | $13M | Series D | – | – | – |
| Dec 2011 | $15M | Series D | – | Bessemer Venture Partners, Lilly Ventures | – |
| Nov 2010 | $24M | Series C | – | Lilly Ventures | |
| Oct 2010 | $1.5M | Series B | – | – | – |
| Jun 2010 | $5M | Series B | – | – | – |
| Jul 2009 | $10M | Series B | – | Polaris Partners, Venrock | – |
| Jan 2008 | $8.1M | Series B | – | – |
8 investors in total: 8 institutional.
Investors in Cerulean Pharma
Cerulean Pharma has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Bessemer Venture Partners and Daré Bioscience.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Venture capital investments and support for entrepreneurs in technology and innovation sectors. | 1911 | bvp.com | Redwood City, United States | |
Early-stage life sciences investments are targeted in the healthcare sector. | – | lillyventures.com | Indianapolis, United States | |
Seed and early-stage technology companies are funded by Lux Capital. | – | luxcapital.com | Menlo Park, United States | |
US focused venture capital firm | – | polarispartners.com | Boston, United States | |
Venture capital firm focused on tech sectors | – | venrock.com | Palo Alto, United States | |
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
Non-hormonal pharmaceutical products for female contraceptives are developed. | 2005 | darebioscience.com | San Diego, United States |
Investor details for Cerulean Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Cerulean Pharma
5 dated milestones of Cerulean Pharma across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Cerulean Pharma is founded.
- Funding First funding round of $12.1M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
- Exit Acquired by Daré Bioscience.
Competitors of Cerulean Pharma
Cerulean Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Moderna, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Cerulean Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cerulean Pharma
The website of Cerulean Pharma (ceruleanrx.com) receives about 4.6K visits a month.
- Monthly visits4.6K
▲ 25.3% vs previous month
Websites whose visitors overlap most with Cerulean Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
urologyclinicpc.com | urologyclinicpc.com | 100% | – | #4,180,627 | – |
canadamedpharmacy.com | canadamedpharmacy.com | 95% | – | #2,220,360 | – |
Latest news on Cerulean Pharma
Complete news archive for Cerulean Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Cerulean Pharma
10 companies that operate in the same segment as Cerulean Pharma (Nanotechnology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Developer of technologies for analysis of genetic variation and function | 1993 | San Diego, California, United States | USD 28 M | USD 1.44 M | 29 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Technology tools and systems for molecular scale are developed. | 1959 | Abingdon, Oxfordshire, United Kingdom | – | USD 648.1 M | – | |
Aerogel-based thermal insulation solutions are provided for energy conservation. | 2001 | United States | USD 198.35 M | USD 271.1 M | 554 | |
Nanotech-based electrode materials for supercapacitors are provided. | 2009 | Boston, Massachusetts, United States | USD 163.32 M | – | 66 | |
Instrument systems and software for single-molecule real-time sequencing are developed. | 2004 | Menlo Park, California, United States | USD 395 M | USD 160 M | 575 | |
Nanotech-based wound care products are developed and provided. | 2010 | Madison, Wisconsin, United States | USD 22.7 M | – | 35 | |
Conductive nanocoatings are delivered via atomic layer deposition technology. | 2013 | Boulder, Colorado, United States | USD 202.75 M | – | – | |
RNA therapeutics for hematology and cardiovascular diseases are developed. | 1999 | London, England, United Kingdom | – | USD 559 K | 116 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cerulean Pharma
Cerulean Pharma was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Cerulean Pharma is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Cerulean Pharma is a funded company, having raised a total of $88.7M across 11 funding rounds to date. The company's 1st funding round was a Series B of $8.1M, raised on Mar 2007.
Cerulean Pharma has 20 employees.
Cerulean Pharma, formerly Tempo Pharmaceuticals, is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The company has a Dynamic Tumor Targeting Platform to create a portfolio of nanoparticle-drug conjugates, or NDCs, designed to selectively attack tumor cells, reduce toxicity by sparing the bodys normal cells, and enable therapeutic combinations.Their lead product candidate, CRLX101, is in multiple clinical trials with other cancer treatments as part of a combination therapy.
Cerulean Pharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Cerulean Pharma offers Prescription Medications, Over-the-Counter Drugs, and Generic Drugs.
Cerulean Pharma has 8 investors. Key investors include ARE, Bessemer Venture Partners, Daré Bioscience, Hercules Capital, and Lilly Ventures.
Cerulean Pharma operates through Cerulean Pharma Inc..
Yes. Cerulean Pharma was acquired by Daré Bioscience in March 2017.